Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04683939
Title Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy Trial of BNT141 in Patients With Unresectable or Metastatic CLDN18.2-positive Gastric, Pancreatic, Ovarian and Biliary Tract Tumors
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors BioNTech SE
Indications

esophagus adenocarcinoma

ovarian mucinous neoplasm

ovarian mucinous cystadenocarcinoma

lung non-small cell carcinoma

ovarian mucinous adenocarcinoma

stomach cancer

colorectal cancer

pancreatic adenocarcinoma

endocervical adenocarcinoma

biliary tract cancer

gastroesophageal junction adenocarcinoma

pancreatic cancer

Therapies

BNT141

BNT141 + Gemcitabine + Nab-paclitaxel

Age Groups: adult | senior
Covered Countries USA | ESP | CAN


No variant requirements are available.